Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Inflammatory Bowel Diseases

  Free Subscription


Articles published in Scand J Gastroenterol

Retrieve available abstracts of 145 articles:
HTML format
Text format



Single Articles


    June 2019
  1. YLISAUKKO-OJA T, Torvinen S, Ventola H, Schmidt S, et al
    Healthcare resource utilization and treatment costs of Finnish chronic inflammatory bowel disease patients treated with infliximab().
    Scand J Gastroenterol. 2019 Jun 16:1-7. doi: 10.1080/00365521.2019.1627579.
    PubMed     Text format     Abstract available


  2. VAN ASSELDONK DP, Simsek M, de Boer NKH, Jharap B, et al
    Limited relevance and progression of histological alterations in the liver during thioguanine therapy in inflammatory bowel disease patients.
    Scand J Gastroenterol. 2019 Jun 16:1-8. doi: 10.1080/00365521.2019.1629006.
    PubMed     Text format     Abstract available


    May 2019
  3. NARULA N, Lauzon B, Marshall JK
    Higher adalimumab serum levels do not increase the risk of adverse events in patients with inflammatory bowel disease.
    Scand J Gastroenterol. 2019 May 30:1-6. doi: 10.1080/00365521.2019.1621367.
    PubMed     Text format     Abstract available


  4. KOLEHMAINEN S, Lepisto A, Farkkila M
    Impact of anti-TNF-alpha therapy on colectomy rate and indications for colectomy in ulcerative colitis: comparison of two patient cohorts from 2005 to 2007 and from 2014 to 2016().
    Scand J Gastroenterol. 2019 May 28:1-5. doi: 10.1080/00365521.2019.1620326.
    PubMed     Text format     Abstract available


  5. BERENDS SE, Strik AS, Jansen JM, de Boer NK, et al
    Pharmacokinetics of golimumab in moderate to severe ulcerative colitis: the GO-KINETIC study.
    Scand J Gastroenterol. 2019 May 27:1-7. doi: 10.1080/00365521.2019.1619828.
    PubMed     Text format     Abstract available


  6. COENEN S, Weyts E, Geens P, Vermeire S, et al
    Short Health Scale: a valid and reliable measure of quality of life in Dutch speaking patients with inflammatory bowel disease.
    Scand J Gastroenterol. 2019 May 18:1-5. doi: 10.1080/00365521.2019.1616214.
    PubMed     Text format     Abstract available


  7. LIU Y, Liu X
    Research progress of P2X7 receptor in inflammatory bowel disease.
    Scand J Gastroenterol. 2019 May 6:1-7. doi: 10.1080/00365521.2019.1609077.
    PubMed     Text format     Abstract available


  8. CHEN HX, Yuan ZY, Wu KX, Liu C, et al
    The study of methylation and single nucleotide polymorphisms of cancer-related genes in patients with early-stage ulcerative colitis.
    Scand J Gastroenterol. 2019 May 2:1-5. doi: 10.1080/00365521.2019.1594355.
    PubMed     Text format     Abstract available


    April 2019
  9. DILILLO D, Zuccotti GV, Galli E, Meneghin F, et al
    Noninvasive testing in the management of children with suspected inflammatory bowel disease.
    Scand J Gastroenterol. 2019 Apr 28:1-6. doi: 10.1080/00365521.2019.1604799.
    PubMed     Text format     Abstract available


  10. SARAIVA S, Cortez-Pinto J, Barosa R, Castela J, et al
    Evaluation of fatigue in inflammatory bowel disease - a useful tool in daily practice.
    Scand J Gastroenterol. 2019 Apr 23:1-6. doi: 10.1080/00365521.2019.1602669.
    PubMed     Text format     Abstract available


  11. RODRIGUEZ-LAGO I, Sempere L, Gutierrez A, Nunez A, et al
    Granulocyte-monocyte apheresis: an alternative combination therapy after loss of response to anti-TNF agents in ulcerative colitis.
    Scand J Gastroenterol. 2019 Apr 14:1-6. doi: 10.1080/00365521.2019.1600715.
    PubMed     Text format     Abstract available


  12. COLD F, Browne PD, Gunther S, Halkjaer SI, et al
    Multidonor FMT capsules improve symptoms and decrease fecal calprotectin in ulcerative colitis patients while treated - an open-label pilot study.
    Scand J Gastroenterol. 2019 Apr 4:1-8. doi: 10.1080/00365521.2019.1585939.
    PubMed     Text format     Abstract available


  13. RIBALDONE DG, Pellicano R, Vernero M, Caviglia GP, et al
    Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysis.
    Scand J Gastroenterol. 2019 Apr 4:1-7. doi: 10.1080/00365521.2019.1597159.
    PubMed     Text format     Abstract available


    March 2019
  14. NIELSEN HM, Dalager-Pedersen M, Nielsen H
    Risk of inflammatory bowel disease after Campylobacter jejuni and Campylobacter concisus infection: a population-based cohort study.
    Scand J Gastroenterol. 2019 Mar 24:1-8. doi: 10.1080/00365521.2019.1578406.
    PubMed     Text format     Abstract available


  15. SAFAEIAN R, Howarth GS, Lawrance IC, Trinder D, et al
    Emu Oil reduces disease severity in a mouse model of chronic ulcerative colitis.
    Scand J Gastroenterol. 2019 Mar 23:1-8. doi: 10.1080/00365521.2019.1581253.
    PubMed     Text format     Abstract available


    February 2019
  16. VENTURIERI MO, Komati JTS, Lopes LHC, Sdepanian VL, et al
    Treatment with Noripurum EV((R)) is effective and safe in pediatric patients with inflammatory bowel disease and iron deficiency anemia.
    Scand J Gastroenterol. 2019 Feb 20:1-7. doi: 10.1080/00365521.2019.1570326.
    PubMed     Text format     Abstract available


  17. DIGNASS AU, Siegmund B, Goertz R, Schneidewind G, et al
    Indirect comparison of vedolizumab and adalimumab for biologic-naive patients with ulcerative colitis.
    Scand J Gastroenterol. 2019 Feb 8:1-10. doi: 10.1080/00365521.2019.1569124.
    PubMed     Text format     Abstract available


    January 2019
  18. EVERHOV AH, Sachs MC, Malmborg P, Nordenvall C, et al
    Changes in inflammatory bowel disease subtype during follow-up and over time in 44,302 patients.
    Scand J Gastroenterol. 2019 Jan 31:1-9. doi: 10.1080/00365521.2018.1564361.
    PubMed     Text format     Abstract available


  19. MOHAN LJ, Daly JS, Ryan BM, Ramtoola Z, et al
    The future of nanomedicine in optimising the treatment of inflammatory bowel disease.
    Scand J Gastroenterol. 2019 Jan 24:1-9. doi: 10.1080/00365521.2018.1563805.
    PubMed     Text format     Abstract available


  20. BUER LCT, Moum BA, Cvancarova M, Warren DJ, et al
    Real world data on effectiveness, safety and therapeutic drug monitoring of vedolizumab in patients with inflammatory bowel disease. A single center cohort.
    Scand J Gastroenterol. 2019 Jan 16:1-8. doi: 10.1080/00365521.2018.1548646.
    PubMed     Text format     Abstract available


  21. VESTERGAARD T, Jorgensen SMD, Christensen LA, Julsgaard M, et al
    Pregnancy outcome in four women with inflammatory bowel disease treated with budesonide MMX.
    Scand J Gastroenterol. 2019 Jan 6:1-4. doi: 10.1080/00365521.2018.1533583.
    PubMed     Text format     Abstract available


  22. MOLANDER P, Jussila A, Toivonen T, Makkeli P, et al
    The impacts of an inflammatory bowel disease nurse specialist on the quality of care and costs in Finland.
    Scand J Gastroenterol. 2019 Jan 2:1-6. doi: 10.1080/00365521.2018.1541477.
    PubMed     Text format     Abstract available


  23. CHOUKOUR M, Kivits J, Baker A, Baumann C, et al
    Personalised medicine in inflammatory bowel diseases: a patient survey.
    Scand J Gastroenterol. 2019;54:135.
    PubMed     Text format    


  24. MONTEIRO S, Dias de Castro F, Leite S, Moreira MJ, et al
    Low fecal calprotectin predicts clinical remission in Crohn's disease patients: the simple answer to a challenging question.
    Scand J Gastroenterol. 2019;54:49-54.
    PubMed     Text format     Abstract available


    December 2018
  25. PROUDFOOT H, Norton C, Artom M, Didymus E, et al
    Targets for interventions for faecal incontinence in inflammatory bowel disease: a systematic review.
    Scand J Gastroenterol. 2018;53:1476-1483.
    PubMed     Text format     Abstract available


    November 2018
  26. KALLA R, Boyapati R, Vatn S, Hijos G, et al
    Patients' perceptions of faecal calprotectin testing in inflammatory bowel disease: results from a prospective multicentre patient-based survey.
    Scand J Gastroenterol. 2018 Nov 18:1-6. doi: 10.1080/00365521.2018.1527394.
    PubMed     Text format     Abstract available


    October 2018
  27. TRONSTAD RR, Polushina T, Brattbakk HR, Stansberg C, et al
    Genetic and transcriptional analysis of inflammatory bowel disease-associated pathways in patients with GUCY2C-linked familial diarrhea.
    Scand J Gastroenterol. 2018 Oct 24:1-10. doi: 10.1080/00365521.2018.1521867.
    PubMed     Text format     Abstract available


  28. NISHIO M, Ishii Y, Hashimoto Y, Otake H, et al
    Short- and long-term efficacy of adalimumab salvage therapy after failure of calcineurin inhibitors in steroid-refractory ulcerative colitis.
    Scand J Gastroenterol. 2018 Oct 24:1-9. doi: 10.1080/00365521.2018.1511825.
    PubMed     Text format     Abstract available


  29. OSSUM AM, Palm O, Cvancarova M, Solberg IC, et al
    Peripheral arthritis in patients with long-term inflammatory bowel disease. Results from 20 years of follow-up in the IBSEN study.
    Scand J Gastroenterol. 2018 Oct 24:1-7. doi: 10.1080/00365521.2018.1518482.
    PubMed     Text format     Abstract available


  30. RUNDQUIST S, Eriksson C, Nilsson L, Angelison L, et al
    Clinical effectiveness of golimumab in Crohn's disease: an observational study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG).
    Scand J Gastroenterol. 2018 Oct 24:1-7. doi: 10.1080/00365521.2018.1519597.
    PubMed     Text format     Abstract available


  31. LEE JM, Kim YJ, Lee KM, Yoon H, et al
    Long-term clinical outcome after infliximab discontinuation in patients with inflammatory bowel disease.
    Scand J Gastroenterol. 2018 Oct 23:0-6. doi: 10.1080/00365521.2018.1524024.
    PubMed     Text format     Abstract available


  32. BAGER P, Vestergaard C, Juul T, Dahlerup JF, et al
    Population-based normative data for the inflammatory bowel disease fatigue scale - IBD-F.
    Scand J Gastroenterol. 2018 Oct 23:1-6. doi: 10.1080/00365521.2018.1521868.
    PubMed     Text format     Abstract available


  33. O'MORAIN N, O'Gorman S, McNamara D, Ryan B, et al
    Patients' attitudes toward treatment withdrawal in inflammatory bowel disease.
    Scand J Gastroenterol. 2018 Oct 9:1. doi: 10.1080/00365521.2018.1511827.
    PubMed     Text format    


  34. KATARINA PL, Sussanne B, Gunilla HF, Henrik H, et al
    The quality of care questionnaire: development of a valid measure for persons with inflammatory bowel disease.
    Scand J Gastroenterol. 2018 Oct 9:1-8. doi: 10.1080/00365521.2018.1495759.
    PubMed     Text format     Abstract available


    September 2018
  35. STEIN J, Walper A, Klemm W, Farrag K, et al
    Safety and efficacy of intravenous iron isomaltoside for correction of anaemia in patients with inflammatory bowel disease in everyday clinical practice.
    Scand J Gastroenterol. 2018 Sep 17:1-7. doi: 10.1080/00365521.2018.1498914.
    PubMed     Text format     Abstract available


  36. LIRHUS SS, Hoivik ML, Moum B, Melberg HO, et al
    Regional differences in anti-TNF-alpha therapy and surgery in the treatment of inflammatory bowel disease patients: a Norwegian nationwide cohort study.
    Scand J Gastroenterol. 2018 Sep 12:1-6. doi: 10.1080/00365521.2018.1495258.
    PubMed     Text format     Abstract available


  37. HUGUET JM, Iborra M, Bosca-Watts MM, Maroto N, et al
    Inflammatory bowel disease in patients over the age of 70 y. Does the disease duration influence its behavior?
    Scand J Gastroenterol. 2018 Sep 6:1-6. doi: 10.1080/00365521.2018.1501603.
    PubMed     Text format     Abstract available


  38. HAAPAMAKI J, Heikkinen E, Sipponen T, Roine RP, et al
    The impact of an adaptation course on health-related quality of life and functional capacity of patients with inflammatory bowel disease.
    Scand J Gastroenterol. 2018 Sep 2:1-5. doi: 10.1080/00365521.2018.1500639.
    PubMed     Text format     Abstract available


  39. JUDIT BERES N, Kiss Z, Muller KE, Cseh A, et al
    Role of microRNA-223 in the regulation of poly(ADP-ribose) polymerase in pediatric patients with Crohn's disease.
    Scand J Gastroenterol. 2018;53:1066-1073.
    PubMed     Text format     Abstract available


  40. SEGAL JP, Penez L, Mohsen Elkady S, Worley GHT, et al
    Long term outcomes of initial infliximab therapy for inflammatory pouch pathology: a multi-Centre retrospective study.
    Scand J Gastroenterol. 2018;53:1051-1058.
    PubMed     Text format     Abstract available


  41. VERSTOCKT B, Vermeire S, Van Assche G, Ferrante M, et al
    When IBD is not IBD.
    Scand J Gastroenterol. 2018;53:1085-1088.
    PubMed     Text format     Abstract available


  42. LI H, Gong Y, Xie Y, Sun Q, et al
    Clostridium butyricum protects the epithelial barrier by maintaining tight junction protein expression and regulating microflora in a murine model of dextran sodium sulfate-induced colitis.
    Scand J Gastroenterol. 2018;53:1031-1042.
    PubMed     Text format     Abstract available


    August 2018
  43. BUHL S, Kristina Borghede M, Brynskov J, Steenholdt C, et al
    Outcome of continued infliximab therapy in Crohn's disease patients with response but without remission after one year of infliximab - a retrospective cohort study.
    Scand J Gastroenterol. 2018;53:930-937.
    PubMed     Text format     Abstract available


  44. HOLLERAN G, Valerii G, Tortora A, Scaldaferri F, et al
    The use of single balloon enteroscopy in Crohn's disease and its impact on clinical outcome.
    Scand J Gastroenterol. 2018;53:925-929.
    PubMed     Text format     Abstract available


    July 2018
  45. VITIKAINEN K, Haapamaki J, Farkkila M, Anttila VJ, et al
    Clostridium difficile infection in patients with inflammatory bowel disease: a case control study.
    Scand J Gastroenterol. 2018 Jul 25:1-5. doi: 10.1080/00365521.2018.1492012.
    PubMed     Text format     Abstract available


  46. DROBNE D, Kurent T, Golob S, Svegl P, et al
    Success and safety of high infliximab trough levels in inflammatory bowel disease.
    Scand J Gastroenterol. 2018 Jul 10:1-7. doi: 10.1080/00365521.2018.1486882.
    PubMed     Text format     Abstract available


  47. RIBALDONE DG, Vernero M, Astegiano M, Pellicano R, et al
    How ameliorate the adherence in patients with inflammatory bowel disease?
    Scand J Gastroenterol. 2018 Jul 3:1-2. doi: 10.1080/00365521.2018.1485731.
    PubMed     Text format    


  48. CARLSEN K, Riis LB, Elsberg H, Maagaard L, et al
    The sensitivity of fecal calprotectin in predicting deep remission in ulcerative colitis.
    Scand J Gastroenterol. 2018 Jul 3:1-6. doi: 10.1080/00365521.2018.1482956.
    PubMed     Text format     Abstract available


    June 2018
  49. XIE D, Zhang Y, Qu H
    Crucial genes of inflammatory bowel diseases explored by gene expression profiling analysis.
    Scand J Gastroenterol. 2018;53:685-691.
    PubMed     Text format     Abstract available


  50. HOIVIK ML, Buer LCT, Cvancarova M, Warren DJ, et al
    Switching from originator to biosimilar infliximab - real world data of a prospective 18 months follow-up of a single-centre IBD population.
    Scand J Gastroenterol. 2018;53:692-699.
    PubMed     Text format     Abstract available


  51. YAKYMENKO O, Schoultz I, Gullberg E, Strom M, et al
    Infliximab restores colonic barrier to adherent-invasive E. coli in Crohn's disease via effects on epithelial lipid rafts.
    Scand J Gastroenterol. 2018;53:677-684.
    PubMed     Text format     Abstract available


  52. SEGAL JP, Chan H, Collins B, Faiz OD, et al
    Biofeedback in patients with ileoanal pouch dysfunction: a specialist centre experience.
    Scand J Gastroenterol. 2018;53:665-669.
    PubMed     Text format     Abstract available


  53. SCHULZE H, Esters P, Hartmann F, Stein J, et al
    A prospective cohort study to assess the relevance of vedolizumab drug level monitoring in IBD patients.
    Scand J Gastroenterol. 2018;53:670-676.
    PubMed     Text format     Abstract available


    May 2018
  54. YADAV A, Foromera J, Falchuk KR, Feuerstein JD, et al
    Biologics and immunomodulators for treating Crohn's disease developing after surgery for an initial diagnosis of ulcerative colitis: a review of current literature.
    Scand J Gastroenterol. 2018 May 2:1-5. doi: 10.1080/00365521.2018.1468478.
    PubMed     Text format     Abstract available


    April 2018
  55. YERUSHALMY-FELER A, Ben-Tov A, Weintraub Y, Amir A, et al
    High and low body mass index may predict severe disease course in children with inflammatory bowel disease.
    Scand J Gastroenterol. 2018 Apr 24:1-6. doi: 10.1080/00365521.2018.1464595.
    PubMed     Text format     Abstract available


  56. RATNAKUMARAN R, To N, Gracie DJ, Selinger CP, et al
    Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience.
    Scand J Gastroenterol. 2018 Apr 24:1-8. doi: 10.1080/00365521.2018.1464203.
    PubMed     Text format     Abstract available


  57. KANG EA, Yoon H, Seo AY, Shin CM, et al
    Characteristics of cytomegalovirus enterocolitis in patients with or without inflammatory bowel diseases.
    Scand J Gastroenterol. 2018;53:453-458.
    PubMed     Text format     Abstract available


  58. SONG EM, Kim N, Lee SH, Chang K, et al
    Clinical characteristics and long-term prognosis of elderly-onset Crohn's disease.
    Scand J Gastroenterol. 2018;53:417-425.
    PubMed     Text format     Abstract available


  59. XAVIER S, Curdia Goncalves T, Dias de Castro F, Magalhaes J, et al
    Perianal Crohn's disease - association with significant inflammatory activity in proximal small bowel segments.
    Scand J Gastroenterol. 2018;53:426-429.
    PubMed     Text format     Abstract available


    March 2018
  60. KEIL R, Wasserbauer M, Zadorova Z, Kojecky V, et al
    Adherence, risk factors of non-adherence and patient's preferred treatment strategy of mesalazine in ulcerative colitis: multicentric observational study.
    Scand J Gastroenterol. 2018 Mar 21:1-7. doi: 10.1080/00365521.2018.1451915.
    PubMed     Text format     Abstract available


  61. WICKBOM A, Bohr J, Nyhlin N, Eriksson A, et al
    Microscopic colitis in patients with ulcerative colitis or Crohn's disease: a retrospective observational study and review of the literature.
    Scand J Gastroenterol. 2018 Mar 16:1-7. doi: 10.1080/00365521.2018.1430252.
    PubMed     Text format     Abstract available


  62. AHLUWALIA B, Moraes L, Magnusson MK, Ohman L, et al
    Immunopathogenesis of inflammatory bowel disease and mechanisms of biological therapies.
    Scand J Gastroenterol. 2018 Mar 9:1-11. doi: 10.1080/00365521.2018.1447597.
    PubMed     Text format     Abstract available


  63. DIGNASS A, Akbar A, Baumgart DC, Bommelaer G, et al
    Granulocyte/monocyte adsorptive apheresis for the treatment of therapy-refractory chronic active ulcerative colitis.
    Scand J Gastroenterol. 2018 Mar 7:1-7. doi: 10.1080/00365521.2018.1447598.
    PubMed     Text format     Abstract available


  64. ZAGOROWICZ E, Przybysz A, Szlak J, Magdziak A, et al
    Detection of cytomegalovirus by immunohistochemistry of colonic biopsies and quantitative blood polymerase chain reaction: evaluation of agreement in ulcerative colitis.
    Scand J Gastroenterol. 2018 Mar 7:1-7. doi: 10.1080/00365521.2018.1447596.
    PubMed     Text format     Abstract available


  65. AALTONEN G, Ristimaki A, Keranen I, Carpelan-Holmstrom M, et al
    Does a histologically inflamed resection margin increase postoperative complications in patients with Crohn's disease?
    Scand J Gastroenterol. 2018;53:279-283.
    PubMed     Text format     Abstract available


    February 2018
  66. KANGASPUNTA M, Haapamaki J, Farkkila M, Arkkila P, et al
    Inflammatory bowel disease and anemia: intravenous iron treatment.
    Scand J Gastroenterol. 2018 Feb 22:1-5. doi: 10.1080/00365521.2018.1441435.
    PubMed     Text format     Abstract available


  67. GREENSTEIN RJ, Brown ST
    A data-based hypothesis explicating the observations that "Smoking is associated with risk for developing inflammatory bowel disease including late onset ulcerative colitis: a prospective study".
    Scand J Gastroenterol. 2018 Feb 15:1. doi: 10.1080/00365521.2018.1440003.
    PubMed     Text format    


  68. HAKIMIAN S, Kheder J, Arum S, Cave DR, et al
    Re-evaluating osteoporosis and fracture risk in Crohn's disease patients in the era of TNF-alpha inhibitors.
    Scand J Gastroenterol. 2018;53:168-172.
    PubMed     Text format     Abstract available


    January 2018
  69. MOORE C
    Response to "Clinical implications of assay-specific differences in f-calprotectin when monitoring inflammatory bowel disease activity over time".
    Scand J Gastroenterol. 2018 Jan 31:1. doi: 10.1080/00365521.2018.1428400.
    PubMed     Text format    


  70. KLEPP P, Kisiel JB, Smastuen MC, Roseth A, et al
    Multi-target stool DNA test in the surveillance of inflammatory bowel disease: a cross-sectional cohort study.
    Scand J Gastroenterol. 2018 Jan 9:1-6. doi: 10.1080/00365521.2018.1424935.
    PubMed     Text format     Abstract available


  71. LINDSTROM L, Jorgensen KK, Boberg KM, Castedal M, et al
    Risk factors and prognosis for recurrent primary sclerosing cholangitis after liver transplantation: a Nordic Multicentre Study.
    Scand J Gastroenterol. 2018 Jan 4:1-8. doi: 10.1080/00365521.2017.1421705.
    PubMed     Text format     Abstract available


  72. SUNDE ML, Ricanek P, Oresland T, Jahnsen J, et al
    Determinants of optimal bowel function in ileal pouch-anal anastomosis - physiological differences contributing to pouch function.
    Scand J Gastroenterol. 2018;53:8-14.
    PubMed     Text format     Abstract available


  73. PALATKA K, Kacska S, Lovas S, Garai I, et al
    The potential role of FDG PET-CT in the characterization of the activity of Crohn's disease, staging follow-up and prognosis estimation: a pilot study.
    Scand J Gastroenterol. 2018;53:24-30.
    PubMed     Text format     Abstract available


    December 2017
  74. SALIH A, Widbom L, Hultdin J, Karling P, et al
    Smoking is associated with risk for developing inflammatory bowel disease including late onset ulcerative colitis: a prospective study.
    Scand J Gastroenterol. 2017 Dec 21:1-6. doi: 10.1080/00365521.2017.1418904.
    PubMed     Text format     Abstract available


  75. YLISAUKKO-OJA T, Aaltonen J, Nuutinen H, Blomster T, et al
    High treatment persistence rate and significant endoscopic healing among real-life patients treated with vedolizumab - a Finnish Nationwide Inflammatory Bowel Disease Cohort Study (FINVEDO)().
    Scand J Gastroenterol. 2017 Dec 19:1-10. doi: 10.1080/00365521.2017.1416160.
    PubMed     Text format     Abstract available


  76. RIBALDONE DG, Vernero M, Saracco GM, Pellicano R, et al
    The adherence to the therapy in inflammatory bowel disease: beyond the number of the tablets.
    Scand J Gastroenterol. 2017 Dec 11:1-6. doi: 10.1080/00365521.2017.1405070.
    PubMed     Text format     Abstract available


  77. LIMKETKAI BN, Sepulveda R, Hing T, Shah ND, et al
    Prevalence and factors associated with gluten sensitivity in inflammatory bowel disease.
    Scand J Gastroenterol. 2017 Dec 7:1-5. doi: 10.1080/00365521.2017.1409364.
    PubMed     Text format     Abstract available


    November 2017
  78. GARCIA-PLANELLA E, Manosa M, Chaparro M, Beltran B, et al
    Serial semi-quantitative measurement of fecal calprotectin in patients with ulcerative colitis in remission.
    Scand J Gastroenterol. 2017 Nov 30:1-6. doi: 10.1080/00365521.2017.1410219.
    PubMed     Text format     Abstract available


  79. NISHIDA Y, Hosomi S, Watanabe K, Watanabe K, et al
    Serum interleukin-6 level is associated with response to infliximab in ulcerative colitis.
    Scand J Gastroenterol. 2017 Nov 24:1-7. doi: 10.1080/00365521.2017.1403647.
    PubMed     Text format     Abstract available


  80. KOMPEROD MJ, Sommer C, Mellin-Olsen T, Iversen PO, et al
    Persistent symptoms in patients with Crohn's disease in remission: An exploratory study on the role of diet.
    Scand J Gastroenterol. 2017 Nov 23:1-6. doi: 10.1080/00365521.2017.1397736.
    PubMed     Text format     Abstract available


  81. BAGER P, Chauhan U, Greveson K, Jaghult S, et al
    Systematic review: advice lines for patients with inflammatory bowel disease.
    Scand J Gastroenterol. 2017 Nov 13:1-7. doi: 10.1080/00365521.2017.1401116.
    PubMed     Text format     Abstract available


    October 2017
  82. THEOCHARI NA, Stefanopoulos A, Mylonas KS, Economopoulos KP, et al
    Antibiotics exposure and risk of inflammatory bowel disease: a systematic review.
    Scand J Gastroenterol. 2017 Oct 12:1-7. doi: 10.1080/00365521.2017.1386711.
    PubMed     Text format     Abstract available



  83. Correction to: Carvalho et al., Prevalence of iron deficiency anemia and iron deficiency in a pediatric population with inflammatory bowel disease.
    Scand J Gastroenterol. 2017;52:ii.
    PubMed     Text format    


    September 2017
  84. KRIDIN K, Zelber-Sagi S, Comaneshter D, Cohen AD, et al
    Ulcerative colitis associated with pemphigus: a population-based large-scale study.
    Scand J Gastroenterol. 2017 Sep 28:1-5. doi: 10.1080/00365521.2017.1380839.
    PubMed     Text format     Abstract available


    August 2017
  85. EBERL A, Huoponen S, Pahikkala T, Blom M, et al
    Switching maintenance infliximab therapy to biosimilar infliximab in inflammatory bowel disease patients.
    Scand J Gastroenterol. 2017 Aug 24:1-6. doi: 10.1080/00365521.2017.1369561.
    PubMed     Text format     Abstract available


  86. SAFFOURI G, Gupta A, Loftus EV Jr, Baddour LM, et al
    The incidence and outcomes from Clostridium difficile infection in hospitalized adults with inflammatory bowel disease.
    Scand J Gastroenterol. 2017 Aug 6:1-8. doi: 10.1080/00365521.2017.1362466.
    PubMed     Text format     Abstract available


    July 2017
  87. KHAJAH MA
    The potential role of fecal microbiota transplantation in the treatment of inflammatory Bowel disease.
    Scand J Gastroenterol. 2017 Jul 7:1-13. doi: 10.1080/00365521.2017.1347812.
    PubMed     Text format     Abstract available


    June 2017
  88. SMIDS C, Horjus Talabur Horje CS, Groenen MJM, van Koolwijk EHM, et al
    The value of serum antibodies in differentiating inflammatory bowel disease, predicting disease activity and disease course in the newly diagnosed patient.
    Scand J Gastroenterol. 2017 Jun 29:1-9. doi: 10.1080/00365521.2017.1344875.
    PubMed     Text format     Abstract available


  89. CARVALHO FSG, de Medeiros IA, Antunes H
    Prevalence of iron deficiency anemia and iron deficiency in a pediatric population with inflammatory bowel disease.
    Scand J Gastroenterol. 2017 Jun 23:1-5. doi: 10.1080/00365521.2017.1342137.
    PubMed     Text format     Abstract available



  90. Correction to: Kokkinidis DG, et al. Emerging treatments for ulcerative colitis: a systematic review.
    Scand J Gastroenterol. 2017 Jun 23:1. doi: 10.1080/00365521.2017.1341083.
    PubMed     Text format    


  91. ABOLFOTOUH S, Rautio T, Klintrup K, Helavirta I, et al
    Predictors of quality-of-life after ileal pouch-anal anastomosis in patients with ulcerative colitis.
    Scand J Gastroenterol. 2017 Jun 9:1-8. doi: 10.1080/00365521.2017.1337218.
    PubMed     Text format     Abstract available


  92. CON D, Jackson B, Gray K, De Cruz P, et al
    eHealth for inflammatory bowel disease self-management - the patient perspective.
    Scand J Gastroenterol. 2017 Jun 9:1-8. doi: 10.1080/00365521.2017.1333625.
    PubMed     Text format     Abstract available


  93. ROTHSCHILD B, Rinawi F, Herman Y, Nir O, et al
    Prognostic significance of granulomas in children with Crohn's disease.
    Scand J Gastroenterol. 2017;52.
    PubMed     Text format     Abstract available


  94. CARDILE S, Alterio T, Candusso M, Pietrobattista A, et al
    Autoimmune liver diseases and inflammatory bowel diseases in children: current issues and future perspectives.
    Scand J Gastroenterol. 2017;52.
    PubMed     Text format     Abstract available


    May 2017
  95. MACALUSO FS, Renna S, Maida M, Dimarco M, et al
    Tolerability profile of thiopurines in inflammatory bowel disease: a prospective experience.
    Scand J Gastroenterol. 2017 May 29:1-7. doi: 10.1080/00365521.2017.1333626.
    PubMed     Text format     Abstract available


  96. JACKSON B, Con D, Ma R, Gorelik A, et al
    Health care costs associated with Australian tertiary inflammatory bowel disease care.
    Scand J Gastroenterol. 2017 May 16:1-6. doi: 10.1080/00365521.2017.1323117.
    PubMed     Text format     Abstract available


  97. KOKKINIDIS DG, Bosdelekidou EE, Iliopoulou SM, Tassos AG, et al
    Emerging treatments for ulcerative colitis: a systematic review.
    Scand J Gastroenterol. 2017 May 14:1-9. doi: 10.1080/00365521.2017.1326163.
    PubMed     Text format     Abstract available


  98. SEO H, Chang K, Lee SH, Song EM, et al
    Long-term outcomes of infliximab treatment and predictors of response in 195 patients with ulcerative colitis: a hospital-based cohort study from Korea.
    Scand J Gastroenterol. 2017 May 14:1-7. doi: 10.1080/00365521.2017.1323229.
    PubMed     Text format     Abstract available


  99. MARTELLI L, Colard A, Fontaine F, Deflandre J, et al
    Evaluation of the efficacy of octreotide LAR in the treatment of Crohn's disease associated refractory diarrhea.
    Scand J Gastroenterol. 2017;52:564-569.
    PubMed     Text format     Abstract available


  100. SASIDHARAN S, Yajnik V, Khalili H, Garber J, et al
    Genetic risk factors for serious infections in inflammatory bowel diseases.
    Scand J Gastroenterol. 2017;52:570-576.
    PubMed     Text format     Abstract available


  101. VARMA P, Falconer J, Aga A, Prince HM, et al
    Rituximab-induced Crohn's disease.
    Scand J Gastroenterol. 2017;52:606-608.
    PubMed     Text format     Abstract available


  102. RINAWI F, Assa A, Eliakim R, Mozer-Glassberg Y, et al
    The natural history of pediatric-onset IBD-unclassified and prediction of Crohn's disease reclassification: a 27-year study.
    Scand J Gastroenterol. 2017;52:558-563.
    PubMed     Text format     Abstract available


  103. RYSKA O, Serclova Z, Mestak O, Matouskova E, et al
    Local application of adipose-derived mesenchymal stem cells supports the healing of fistula: prospective randomised study on rat model of fistulising Crohn's disease.
    Scand J Gastroenterol. 2017;52:543-550.
    PubMed     Text format     Abstract available


    April 2017
  104. KWAPISZ L, Gregor J, Chande N, Yan B, et al
    The utility of fecal calprotectin in predicting the need for escalation of therapy in inflammatory bowel disease.
    Scand J Gastroenterol. 2017 Apr 20:1-5. doi: 10.1080/00365521.2017.1315740.
    PubMed     Text format     Abstract available


  105. LEE KE, Jung SA, Yoon H, Park SH, et al
    Factors associated with pregnancy-related knowledge in women of reproductive age with inflammatory bowel disease.
    Scand J Gastroenterol. 2017 Apr 7:1-7. doi: 10.1080/00365521.2017.1310288.
    PubMed     Text format     Abstract available


    March 2017
  106. JAIME F, Riutort MC, Alvarez-Lobos M, Hoyos-Bachiloglu R, et al
    Solar radiation is inversely associated with inflammatory bowel disease admissions.
    Scand J Gastroenterol. 2017 Mar 31:1-8. doi: 10.1080/00365521.2017.1307444.
    PubMed     Text format     Abstract available


  107. ERIKSSON C, Marsal J, Bergemalm D, Vigren L, et al
    Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG).
    Scand J Gastroenterol. 2017 Mar 31:1-8. doi: 10.1080/00365521.2017.1304987.
    PubMed     Text format     Abstract available


  108. WLODARCZYK M, Sobolewska-Wlodarczyk A, Cygankiewicz AI, Jacenik D, et al
    G protein-coupled receptor 55 (GPR55) expresses differently in patients with Crohn's disease and ulcerative colitis.
    Scand J Gastroenterol. 2017 Mar 8:1-5. doi: 10.1080/00365521.2017.1298834.
    PubMed     Text format     Abstract available


  109. MURRAY IA, Murray LK, Woolson KL, Sherfi H, et al
    Incidence and predictive factors for positive 75SeHCAT test: improving the diagnosis of bile acid diarrhoea.
    Scand J Gastroenterol. 2017 Mar 5:1-6. doi: 10.1080/00365521.2017.1298153.
    PubMed     Text format     Abstract available


  110. MARTI-GALLOSTRA M, Myrelid P, Mortensen N, Keshav S, et al
    The role of a defunctioning stoma for colonic and perianal Crohn's disease in the biological era.
    Scand J Gastroenterol. 2017;52:251-256.
    PubMed     Text format     Abstract available


  111. BAR-GIL SHITRIT A, Koslowsky B, Livovsky DM, Shitrit D, et al
    A prospective study of fecal calprotectin and lactoferrin as predictors of small bowel Crohn's disease in patients undergoing capsule endoscopy.
    Scand J Gastroenterol. 2017;52:328-333.
    PubMed     Text format     Abstract available


    February 2017
  112. WALDUM HL, Bjornsson ES, Brenna E
    Chronic cholestatic liver diseases.
    Scand J Gastroenterol. 2017 Feb 28:1. doi: 10.1080/00365521.2017.1296276.
    PubMed     Text format    


  113. BOND A, Dodd S, Fisher G, Skouras T, et al
    Concurrent immunomodulator therapy is associated with higher adalimumab trough levels during scheduled maintenance therapy.
    Scand J Gastroenterol. 2017;52:204-208.
    PubMed     Text format     Abstract available


    January 2017
  114. YE X, Liu S, Hu M, Song Y, et al
    CCR5 expression in inflammatory bowel disease and its correlation with inflammatory cells and beta-arrestin2 expression.
    Scand J Gastroenterol. 2017 Jan 31:1-10. doi: 10.1080/00365521.2017.1281435.
    PubMed     Text format     Abstract available


  115. JACKSON BD, Con D, Liew D, De Cruz P, et al
    Clinicians' adherence to international guidelines in the clinical care of adults with inflammatory bowel disease.
    Scand J Gastroenterol. 2017 Jan 27:1-7. doi: 10.1080/00365521.2017.1278785.
    PubMed     Text format     Abstract available


  116. LANDERHOLM K, Abdalla M, Myrelid P, Andersson RE, et al
    Survival of ileal pouch anal anastomosis constructed after colectomy or secondary to a previous ileorectal anastomosis in ulcerative colitis patients: a population-based cohort study.
    Scand J Gastroenterol. 2017 Jan 19:1-5. doi: 10.1080/00365521.2016.1278457.
    PubMed     Text format     Abstract available


  117. RONNBLOM A, Holmstrom T, Karlbom U, Tanghoj H, et al
    Clinical course of Crohn's disease during the first 5 years. Results from a population-based cohort in Sweden (ICURE) diagnosed 2005-2009.
    Scand J Gastroenterol. 2017;52:81-86.
    PubMed     Text format     Abstract available


  118. VALERIO DE AZEVEDO S, Maltez C, Lopes AI
    Pediatric Crohn's disease, iron deficiency anemia and intravenous iron treatment: a follow-up study.
    Scand J Gastroenterol. 2017;52:29-33.
    PubMed     Text format     Abstract available


  119. BEAUPEL N, Brouquet A, Abdalla S, Carbonnel F, et al
    Preoperative oral polymeric diet enriched with transforming growth factor-beta 2 (Modulen) could decrease postoperative morbidity after surgery for complicated ileocolonic Crohn's disease.
    Scand J Gastroenterol. 2017;52:5-10.
    PubMed     Text format     Abstract available


    December 2016
  120. GRIMSTAD T, Skoie IM, Doerner J, Isaksen K, et al
    TWEAK is not elevated in patients with newly diagnosed inflammatory bowel disease.
    Scand J Gastroenterol. 2016 Dec 31:1-5. doi: 10.1080/00365521.2016.1273382.
    PubMed     Text format     Abstract available


  121. CANCADO GG, Vilela EG
    Guillain-Barre syndrome during adalimumab therapy for Crohn s disease: coincidence or consequence?
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  122. LAURELL A, Sjoberg K
    Prebiotics and synbiotics in ulcerative colitis.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  123. BROMS G, Granath F, Stephansson O, Kieler H, et al
    Preterm birth in women with inflammatory bowel disease - the association with disease activity and drug treatment.
    Scand J Gastroenterol. 2016;51:1462-1469.
    PubMed     Text format     Abstract available


    November 2016
  124. OLBJORN C, Cvancarova Smastuen M, Thiis-Evensen E, Nakstad B, et al
    Serological markers in diagnosis of pediatric inflammatory bowel disease and as predictors for early tumor necrosis factor blocker therapy.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  125. AMCOFF K, Stridsberg M, Lampinen M, Magnuson A, et al
    Clinical implications of assay specific differences in f-calprotectin when monitoring inflammatory bowel disease activity over time.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  126. LANKARANI KB, Sepehrimanesh M, Seghatoleslami F, Hoseini SE, et al
    Autophagy-related protein 7 level in patients with ulcerative colitis.
    Scand J Gastroenterol. 2016.
    PubMed     Text format    


  127. ZHOU G, Yang W, Yu L, Yu T, et al
    CD99 refers to the activity of inflammatory bowel disease.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  128. HUPPERTZ-HAUSS G, Hoivik ML, Jelsness-Jorgensen LP, Opheim R, et al
    Fatigue in a population-based cohort of patients with inflammatory bowel disease 20 years after diagnosis: The IBSEN study.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  129. ENGLUND H, Liden K K, Lind T, Sundstrom T, et al
    Radiation exposure in patients with inflammatory bowel disease and irritable bowel syndrome in the years 2001-2011.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  130. MOLANDER P, Farkkila M, Kemppainen H, Blomster T, et al
    Long-term outcome of inflammatory bowel disease patients with deep remission after discontinuation of TNFalpha-blocking agents.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    October 2016
  131. JAKOBSSON GL, Sternegard E, Olen O, Myrelid P, et al
    Validating inflammatory bowel disease (IBD) in the Swedish National Patient Register and the Swedish Quality Register for IBD (SWIBREG).
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    September 2016
  132. HOGBERG C, Karling P, Rutegard J, Lilja M, et al
    Diagnosing colorectal cancer and inflammatory bowel disease in primary care: The usefulness of tests for faecal haemoglobin, faecal calprotectin, anaemia and iron deficiency. A prospective study.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  133. MUTHAS D, Reznichenko A, Balendran CA, Bottcher G, et al
    Neutrophils in Ulcerative Colitis: A review of selected biomarkers and their potential therapeutic implications.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    August 2016
  134. LEHTOLA E, Haapamaki J, Farkkila MA
    Outcome of inflammatory bowel disease patients treated with TNF-alpha inhibitors: two-year follow-up.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  135. KISZKA-KANOWITZ M, Theede K, Mertz-Nielsen A
    Randomized clinical trial: a pilot study comparing efficacy of low-dose azathioprine and allopurinol to azathioprine on clinical outcomes in inflammatory bowel disease.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  136. PROSBERG M, Bendtsen F, Vind I, Petersen AM, et al
    The association between the gut microbiota and the inflammatory bowel disease activity: a systematic review and meta-analysis.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    July 2016
  137. HOLT DQ, Strauss BJ, Lau KK, Moore GT, et al
    Body composition analysis using abdominal scans from routine clinical care in patients with Crohn's Disease.
    Scand J Gastroenterol. 2016;51:842-7.
    PubMed     Text format     Abstract available


    June 2016
  138. VON VOLKMANN HL, Nylund K, Tronstad RR, Hovdenak N, et al
    An activating gucy2c mutation causes impaired contractility and fluid stagnation in the small bowel.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    January 2016
  139. MOUSSATA D, Boschetti G, Stefanescu C, Nancey S, et al
    Isolated ileitis associated with primary sclerosing cholangitis in three patients with Crohn's disease.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  140. FERREIRO-IGLESIAS R, Barreiro-de Acosta M, Lorenzo-Gonzalez A, Dominguez-Munoz JE, et al
    Usefulness of a rapid faecal calprotectin test to predict relapse in Crohn's disease patients on maintenance treatment with adalimumab.
    Scand J Gastroenterol. 2016;51:442-7.
    PubMed     Text format     Abstract available


  141. PARK SK, Hong M, Ye BD, Kim KJ, et al
    Influences of XDH genotype by gene-gene interactions with SUCLA2 for thiopurine-induced leukopenia in Korean patients with Crohn's disease.
    Scand J Gastroenterol. 2016;51:684-91.
    PubMed     Text format     Abstract available


  142. DIGE A, Magnusson MK, Ohman L, Hvas CL, et al
    Reduced numbers of mucosal DR(int) macrophages and increased numbers of CD103(+) dendritic cells during anti-TNF-alpha treatment in patients with Crohn's disease.
    Scand J Gastroenterol. 2016;51:692-9.
    PubMed     Text format     Abstract available


  143. GABRYEL M, Skrzypczak-Zielinska M, Kucharski MA, Slomski R, et al
    The impact of genetic factors on response to glucocorticoids therapy in IBD.
    Scand J Gastroenterol. 2016;51:654-65.
    PubMed     Text format     Abstract available


  144. HERRANZ BACHILLER MT, Barrio Andres J, Fernandez Salazar L, Ruiz-Zorrilla R, et al
    The utility of faecal calprotectin to predict post-operative recurrence in Crohns disease.
    Scand J Gastroenterol. 2016;51:720-6.
    PubMed     Text format     Abstract available


  145. COELHO R, Magro F, Silva M, Macedo G, et al
    Early surgery in Crohn's disease patients with entero-urinary fistulas: does it change the prognosis?
    Scand J Gastroenterol. 2016;51:679-83.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: